U.S. Other Utilities Stock News

NasdaqGS:EXE
NasdaqGS:EXEOil and Gas

Is It Time To Reassess Expand Energy (EXE) After The Recent Share Price Pullback

If you are wondering whether Expand Energy at US$104.67 is still worth your attention or if most of the upside has already been priced in, this article breaks down what the current share price might be implying about value. The stock has recently seen a 3.1% decline over 7 days and is down 5.2% over 30 days, even though the 1-year return sits at 7.6% and the 5-year return is a very large gain of around 2x. Recent coverage around Expand Energy has focused on its position within the energy...
NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN)

BioMarin Pharmaceutical Inc. recently received FDA approval for a supplemental Biologics License Application expanding PALYNZIQ (pegvaliase-pqpz) use to pediatric phenylketonuria patients aged 12 and older, based on PEGASUS Phase 3 safety and efficacy data. This approval broadens PALYNZIQ’s eligible patient population but comes with a REMS restriction due to immune-mediated risks including anaphylaxis, highlighting both opportunity and safety management demands for BioMarin. We’ll now...
NYSE:ETN
NYSE:ETNElectrical

Eaton’s SPAN Smart-Panel Bet Might Change The Case For Investing In Eaton (ETN)

In early March 2026, Eaton announced a partnership with SPAN, investing US$75,000,000 to co-develop smart electrical panels that support affordable home electrification and reduce grid infrastructure needs, with joint solutions targeted for release in the second quarter of 2026. This move extends Eaton’s “Home as a Grid” approach by pairing its distribution and protection hardware with SPAN’s energy intelligence software, potentially deepening Eaton’s role in managing household energy use...
NYSE:BUR
NYSE:BURDiversified Financial

A Look At Burford Capital’s Valuation After Q4 2025 Earnings, Insider Buying And New Buyback Program

Burford Capital (NYSE:BUR) has been in focus after its Q4 2025 earnings showed lower revenue, a quarterly net loss, and reduced earnings per share, alongside insider share purchases and a new repurchase program. See our latest analysis for Burford Capital. At a share price of US$8.28, Burford Capital has had a softer run recently, with a 30 day share price return of 7.17% and a year to date share price return of 5.37%. The 1 year total shareholder return of a 36.94% decline contrasts with...
NYSE:CW
NYSE:CWAerospace & Defense

Curtiss-Wright (CW) Valuation Check After New Aerospace Partnership And Defense Contract Wins

What the recent aerospace deals tell you about Curtiss-Wright Curtiss-Wright (CW) has been in focus after two recent aerospace and defense wins: a new partnership with Averna to build custom aerospace test systems and a four year U.S. Department of Defense contract for helicopter support equipment. See our latest analysis for Curtiss-Wright. The recent Averna partnership and U.S. Department of Defense contract arrive as Curtiss-Wright’s share price trades at US$703.61, with a 30-day share...
NYSE:RCUS
NYSE:RCUSBiotechs

Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion

Arcus Biosciences recently reported full-year 2025 results, with revenue of US$247 million versus US$258 million in 2024 and a net loss of US$353 million, while also granting new employee equity awards under its 2020 Inducement Plan. More importantly for the story, Arcus outlined encouraging new clinical data and expansion plans for its HIF-2α inhibitor casdatifan in kidney cancer, alongside moves into inflammatory and autoimmune diseases that could reshape how investors view its pipeline...
NYSE:JEF
NYSE:JEFCapital Markets

Does Jefferies (JEF) Face a Credibility Test as Legal Scrutiny Meets Ongoing Debt Issuance Strategy?

In early March 2026, Western Alliance Bancorporation sued Jefferies Financial Group over a US$126.4 million commercial loan tied to allegedly fraudulent First Brands Group receivables, while Jefferies simultaneously continued issuing long-dated senior unsecured notes across multiple fixed-income offerings. Jefferies has firmly rejected Western Alliance’s claims, highlighting the non-recourse structure of the disputed loans and disclosing related regulatory and legal scrutiny, including an...
NYSE:BVN
NYSE:BVNMetals and Mining

A Look At Compañía de Minas Buenaventura (BVN) Valuation After Strong Earnings And Proposed Dividend

Compañía de Minas BuenaventuraA (BVN) has put income and earnings in focus after its board proposed a US$0.9904 per share dividend, alongside detailed fourth quarter and full year 2025 results. See our latest analysis for Compañía de Minas BuenaventuraA. Those earnings and dividend headlines come after a very strong run in the stock, with a 44.99% 90 day share price return, a 36.06% year to date share price return and a 1 year total shareholder return of 192.62%. This suggests momentum has...
NasdaqGS:FTNT
NasdaqGS:FTNTSoftware

Assessing Fortinet (FTNT) Valuation After Recent Share Price Gains And Mixed Earnings Signals

Context for Fortinet after recent performance Fortinet (FTNT) continues to draw attention after recent share price moves, with a 1 day return of 0.5%, about 3.8% over the past week and a modest gain over the past month. Investors are also weighing its roughly 3.2% return over the past 3 months and 8.1% year to date, against a 14.3% negative 1 year total return and longer term gains over 3 and 5 years. See our latest analysis for Fortinet. At a share price of $84.20, Fortinet’s recent positive...
NYSE:TMO
NYSE:TMOLife Sciences

Is Thermo Fisher Scientific (TMO) Fairly Priced After Recent Share Price Weakness?

If you are wondering whether Thermo Fisher Scientific at around US$500 per share still offers solid value, this article will walk through what the current price really implies. The stock is currently around US$500.08, with returns of a 1.6% decline over 7 days, 7.9% decline over 30 days, 15.6% decline year to date, 2.4% decline over 1 year and 9.3% decline over 3 years, while the 5 year return sits at 13.4%. Recent news coverage has focused on Thermo Fisher Scientific's role as a key...
NYSE:NEE
NYSE:NEEElectric Utilities

A Look At NextEra Energy (NEE) Valuation After Chief Risk Officer Resignation Uncertainty

NextEra Energy (NEE) is back in focus after chief risk officer Terrell Kirk Crews II announced his resignation, effective March 20, 2026, leaving investors weighing what this means for risk oversight. See our latest analysis for NextEra Energy. Recent events, including the chief risk officer’s planned exit and a US$2b composite units offering, have come against a backdrop of building momentum. The 30 day share price return of 2.31% and the 90 day share price return of 12.64%, alongside the 1...
NasdaqGS:TLRY
NasdaqGS:TLRYPharmaceuticals

Tilray’s BrewDog Australia Deal Expands Asia Pacific Reach Amid Weak Shares

Tilray Brands has completed its acquisition of BrewDog Brewing Australia, expanding its beverage platform into the Asia Pacific region. The deal adds an Australian production facility, bar network, and new distribution channels to Tilray’s existing BrewDog UK relationship. This move is described by the company as its most significant international step in beverages so far. Tilray Brands, traded as NasdaqGS:TLRY, now pairs its existing BrewDog UK exposure with a direct operating footprint in...
NYSE:OPLN
NYSE:OPLNCommercial Services

Assessing OPENLANE (OPLN) Valuation As Contrasting Fair Value And DCF Signals Emerge

OPENLANE (OPLN) has drawn investor attention after recently trading around US$28.34. Its mixed share performance over the past month and past 3 months has prompted closer scrutiny of its wholesale used vehicle marketplace business. See our latest analysis for OPENLANE. Looking beyond the recent pullback, OPENLANE’s 1 day share price return of 1.73% and 30 day share price return of a 3.70% decline contrast with a 1 year total shareholder return of 36.58% and 3 year total shareholder return of...
NYSE:KSS
NYSE:KSSMultiline Retail

Kohl’s (KSS) Thin 1.8% Net Margin Tests Bullish Earnings Rebound Narrative

Kohl's (KSS) has wrapped up FY 2026 with fourth quarter revenue of US$5,173 million and basic EPS of US$1.12, anchored by net income of US$125 million. Trailing 12 month basic EPS sits at US$2.43 on revenue of US$15,527 million. Over the past few quarters, the company has seen quarterly revenue move from US$3,233 million in Q1 2026 to US$5,173 million in Q4 2026, with basic EPS ranging from a loss of US$0.14 in Q1 2026 to US$1.12 in Q4 2026. Trailing 12 month EPS has risen from US$1.09 at Q1...
NasdaqGM:FLY
NasdaqGM:FLYAerospace & Defense

Is Firefly Aerospace’s (FLY) Block II Test Flight Quietly Reframing Its Long‑Term Competitive Position?

Firefly Aerospace recently conducted its Alpha Flight 7 mission from Vandenberg Space Force Base, serving as the final test flight of the rocket’s Block I configuration while also evaluating several Block II systems in a live launch environment. This combined Block I close‑out and Block II validation flight is important because it aims to accelerate upgrades that are intended to improve Alpha’s reliability, production efficiency and mission versatility across national security, hypersonic...
NasdaqCM:RPAY
NasdaqCM:RPAYDiversified Financial

Repay Holdings RPAY Loss Deepens To US$3.00 TTM EPS Challenging Margin Recovery Narratives

Repay Holdings FY 2025 results: revenue steady, losses weigh on margins Repay Holdings (RPAY) has wrapped up FY 2025 with Q4 revenue of US$78.6 million and a basic EPS loss of US$1.71, capping a year in which trailing 12 month revenue came in at US$309.3 million alongside a net loss of US$256.7 million. Over recent quarters the company has seen quarterly revenue move in a tight band between US$75.6 million and US$79.1 million, while quarterly basic EPS has ranged from a loss of US$1.71 to a...
NasdaqGM:FUTU
NasdaqGM:FUTUCapital Markets

A Look At Futu Holdings (FUTU) Valuation As Optimism Builds Before Upcoming Earnings And Options Activity Grows

Futu Holdings (FUTU) is back in focus as traders position ahead of its imminent fourth quarter and full year 2025 earnings release, with optimism tied to options activity and upbeat analyst commentary. See our latest analysis for Futu Holdings. The recent 7.2% one day share price return to US$153.58 builds on a 6.1% seven day share price gain, yet follows a 90 day share price decline of 11.4%. This leaves the year to date share price return at 13.9% lower, while the one year total shareholder...
NYSEAM:UMAC
NYSEAM:UMACElectronic

Unusual Machines (UMAC) Q4 Revenue Surge Reinforces Bullish Growth Narratives Despite Ongoing Losses

Unusual Machines (UMAC) has wrapped up FY 2025 with Q4 revenue of US$4.9 million, Basic EPS of a US$0.29 loss, and net income excluding extra items of a US$10.6 million loss, setting a clear snapshot of where the business stands today. Over recent periods the company has seen revenue move from US$2.0 million in Q4 2024 to US$4.9 million in Q4 2025. Quarterly EPS has ranged from a US$2.70 loss in Q4 2024 to a US$0.05 profit in Q3 2025 and back to a US$0.29 loss in the latest quarter,...
NYSE:COTY
NYSE:COTYPersonal Products

Is Coty (COTY) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump

If you are wondering whether Coty's current share price really reflects what the business is worth, it helps to start by separating sentiment from valuation. Coty's share price closed at US$2.33 most recently, with returns of a 4.9% decline over 7 days, a 12.4% decline over 30 days, a 25.1% decline year to date, a 59.1% decline over 1 year, a 78.8% decline over 3 years and a 74.2% decline over 5 years. These moves have kept Coty on the radar for investors who track companies whose share...
NYSE:PAY
NYSE:PAYDiversified Financial

Strong Q4 Beat And Backlog Surge Might Change The Case For Investing In Paymentus (PAY)

Paymentus Holdings recently delivered a strong fourth-quarter update, reporting 28.1% year-over-year revenue growth that exceeded analyst expectations for both revenue and earnings, and highlighted a substantial backlog that extends visibility well into 2026 and beyond. This performance has positioned Paymentus as one of the fastest-growing players in its peer group, underscoring how its bill-pay platform and enterprise relationships are currently converting into meaningful operational...
NasdaqCM:INSE
NasdaqCM:INSEHospitality

Inspired Entertainment (INSE) Returns To Trailing Losses Challenging Profitability Recovery Narrative

Inspired Entertainment (INSE) has just wrapped up FY 2025 with Q4 revenue of US$77.2 million and a basic EPS loss of US$0.25, alongside trailing twelve month revenue of US$304.1 million and a TTM basic EPS loss of US$0.58. Over recent quarters, the company has seen revenue move between US$60.4 million and US$86.2 million, while basic EPS has ranged from a small loss of US$0.00 in Q1 2025 to a profit of US$2.28 in Q4 2024, before settling back into losses through 2025. For investors, these...
NasdaqGS:VSEC
NasdaqGS:VSECAerospace & Defense

Assessing VSE (VSEC) Valuation After A Strong Multi Year Shareholder Return Run

Why VSE (VSEC) is on investors’ radar VSE (VSEC) has drawn attention after a period of strong stock returns, with the share price up about 8% over the past month and roughly 27% in the past 3 months. For investors tracking longer performance, VSE’s total return sits near 19% year to date and about 85% over the past year, with 3 year and 5 year total returns both described as very large multiples of the starting level. See our latest analysis for VSE. Recent trading has been relatively steady,...
NasdaqGM:WLFC
NasdaqGM:WLFCTrade Distributors

Willis Lease Finance (WLFC) Margin Compression Challenges Bullish Growth Narrative After FY 2025 Earnings

Willis Lease Finance (WLFC) has just wrapped up FY 2025 with fourth quarter total revenue of US$193.6 million and basic EPS of US$1.58, while trailing twelve month revenue landed at US$730.2 million and EPS at US$16.00. Over recent periods, the company has seen quarterly revenue move from US$149.1 million in Q4 2024 to US$153.4 million in Q1 2025, US$191.9 million in Q2, US$180.0 million in Q3, and US$193.6 million in Q4, with basic EPS shifting from US$2.97 in Q4 2024 to US$2.34, US$8.68,...
NasdaqGM:XENE
NasdaqGM:XENEBiotechs

Why Xenon Pharmaceuticals (XENE) Is Up 38.4% After Strong Phase 3 Azetukalner Seizure Data And FDA Plans

Xenon Pharmaceuticals recently reported positive topline Phase 3 X-TOLE2 results for azetukalner in highly treatment‑resistant focal onset seizures, with both the 25 mg and 15 mg doses significantly reducing seizure frequency versus placebo and showing a safety profile in line with earlier trials. The data suggest azetukalner could become the only KV7 potassium channel opener for epilepsy if its planned US FDA New Drug Application in the third quarter of 2026 is accepted and ultimately...